A recent study found that women diagnosed with breast cancer are at increased risk for developing thyroid cancer, prompting the authors to encourage regular screening for the disease in breast cancer survivors.
Pfizer announced that the phase III trial of palbociclib was stopped early after meeting its primary endpoint of improved progression-free survival in women with HR–positive, HER2-negative metastatic breast cancer.
More than 90% of women about to undergo a mammography were unable to accurately quantify their risk for breast cancer, either over- or underestimating their risk, according to the results of a large-scale survey presented at the ASCO Breast Cancer Symposium 2013.
Expert radiologists were able to screen magnetic resonance images and rule out breast cancer diagnosis with a negative predictive value of about 99% using an abridged breast MRI protocol in a single-center study presented Saturday at the ASCO Breast Cancer Symposium 2013.
Dr. Bruce Roth discusses the large Danish study reported at ASCO (abstract 4502) that showed surveillance alone is sufficient after orchiectomy for stage I seminoma, focusing on its impact on post-surgery radiation therapy in this setting.